(Il Sole 24 Ore Radiocor) - Milano, 9 mar - Agilent Technologies said it had agreed to buy clinical pathology company Biocare Medical in an all-cash deal worth 950 million dollars.

'The acquisition of Biocare enhances Agilent's pathology portfolio and reflects our strategy to drive long-term growth through customer-centric innovation and disciplined capital allocation,' Agilent president and CEO Padraig McDonnell said.

Agilent, which is buying Biocare from a group led by private-equity firm Excellere Partners and healthcare investor GHO Capital Partners, said the deal would close no later than its fourth fiscal quarter of 2026.

With more than 300 specialized antibodies and a proven R&D capability, Biocare has achieved annual double-digit revenue and profit growth since 2021 and generated over 90 million.

dollars in revenue in 2025, Agilent said.

(RADIOCOR) 09-03-26 14:08:54 (0355) 5 NNNN